Corindus Vascular Robotics will present benefits of its CorPath System during May 29 symposium, “Robotic Precision: A Tool to Standardize Today’s Cath Lab,” at SCAI 2014, May 28 – 31
Waltham, MA – May 21, 2014 – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its CorPath System at the upcoming Society for Cardiovascular Angiography and Interventions (SCAI) 2014 annual scientific session, May 28 – 31 in Las Vegas, NV. CorPath is the first FDA-cleared medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Interventional cardiologists working at leading hospitals and healthcare organizations will share insight on the implementation of robotic technology in cath lab and discuss the benefits the CorPath System offers patients and physicians.
“Robotic Precision: A Tool to Standardize Today’s Cath Lab,” a breakfast symposium on Thursday, May 29, will highlight the physician presentations at 6:30 a.m. PDT at rooms I-II of the Pompeian Ballroom at Caesars Palace Hotel.
Ehtisham Mahmud, M.D., director, Sulpizio Cardiovascular Center-Medicine, UC San Diego, and Giora Weisz, M.D., Shaare Zedek Medical Center will moderate the symposium, titled “Robotic Precision: A Tool to Standardize Today’s Cath Lab.” The symposium will present clinical data and cases demonstrating robotic-assisted percutaneous coronary intervention (PCI) procedures. Attendees will develop an understanding of the benefits of robotic precision as well as the reduced radiation exposure for physicians enabled by the technology. The symposium will close with an audience Q&A and discussion on the ways robotics can enhance angioplasties.
“Tremendous advances have been made in the stent technologies and pharmacologic therapies for percutaneous coronary intervention. However, minimal changes in the procedural technique itself have occurred since the initial description of PCI. Robotic assisted-PCI opens a new frontier in the field enabling improved precision and new novel techniques for performing PCI. Additionally, there is a growing body of evidence that interventionalists face an elevated risk of brain tumors and other malignancies. Robotic-assisted PCI with CorPath is a unique tool that protects the interventionalists by reducing radiation exposure and simultaneously enhancing procedural efficiency.” said Ehtisham Mahmud, MD.
“Corindus is committed to improving clinical outcomes for patients by empowering physicians with the robotic precision and safety afforded by CorPath,” said David Handler, President and CEO of Corindus Vascular Robotics. “This symposium will showcase the critical benefits to both patients and physicians that are possible via robotic-assisted angioplasties.”
“Robotic Precision: A Tool to Standardize Today’s Cath Lab” will feature the following agenda and speakers:
For a hands-on demonstration of robotic angioplasty with the CorPath System, register here and visit SCAI booth #307.
For more information on the symposium, “Robotic Precision: A Tool to Standardize Today’s Cath Lab,” click here. To see the complete SCAI 2014 agenda, please visit http://www.scai.org/SCAI2014/default.aspx.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements:
